PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
50 hedge funds and large institutions have $61.1M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
48% less capital invested
Capital invested by funds: $118M → $61.1M (-$57.4M)
Holders
50
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$540K | |
| 2 | +$447K | |
| 3 | +$326K | |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$156K |
| 5 |
PTP
Platform Technology Partners
New York
|
+$115K |
Top Sellers
| 1 | -$3.03M | |
| 2 | -$1.09M | |
| 3 | -$557K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$404K |
| 5 |
Goldman Sachs
New York
|
-$225K |